Volume : 08, Issue : 06, June – 2021
Title:
34.COMPARE THE EFFECTIVENESS AND SAFETY OF TRIPLE THERAPY VERSUS DUAL ANTI-HYPERTENSIVE THERAPY IN ADULTS
Authors :
(Dr.) Lakhmisetty Priyanka*, (Dr.) Sanikommu Divya Sree, (Dr.) Rallapalli Khadar Basha, (Dr.) Mundlapati Vijaya Raju, Dr. Sk Faizan Ali
Abstract :
Comparing the effectiveness of triple therapy and Dual Anti- Hypertensive therapy in Adults ex-plains the how adults are responding the both the therapies by using the statistical analysis, generally hypertension classified as primary and secondary primary, primary has reasons like life style and secondary has no reasons and hypertensive drugs to be use like telimisartan, Amlodipine are suggestive, the data is collected from different sources and by using statistical tools and techniques like t- test and table analysis the results acquired. Such that double therapy
Cite This Article:
Please cite this article in press Lakhmisetty Priyanka et al., Compare The Effectiveness And Safety Of Triple Therapy Versus Dual Anti-Hypertensive Therapy In Adults.., Indo Am. J. P. Sci, 2021; 08(06).
Number of Downloads : 10
References:
1) The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Cited 2011 September 23. Available from www.nhlbi.nih.gov/guidelines/hypertension.
2) Wright RF, Duprez D, Purkayastha D, Samuel R, Ferdinand KC. Combination Angiotensin- Receptor Blocker (ARB)/Calcium Channel Blocker With HCTZ versus the Maximal Recommended Dose of an ARB With HCTZ in Patients With Stage 2 Hypertension: The Exforge As Compared to Losartan Treatment in Stage 2 Systolic Hypertension (EXALT) Study. J Clin Hypertens. 2011;13:588–97. [PubMed] [Google Scholar].
3) Destro M, Crikelair N, Yen J, Glazer R. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide versus dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vasc Health Risk Manag. 2010;6:82127. [PMC free article] [PubMed] [Google Scholar].
4) Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J. 2000;321:1440–44. [PMC free article] [PubMed] [Google Scholar].
5) Nakao N, Yoshimura A, Morita H, Takada M, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117–24. [PubMed] [Google Scholar].
6) Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, et al. VALsartan In Acute myocardial iNfarcTion (valiant) trial: baseline characteristics in context. Eur J Heart Fail. 2003;5(4):537–44. [PubMed] [Google Scholar].
7) Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59. [PubMed] [Google Scholar].
8) Geiger H, Barranco E, Gorostidi M, Taylor A, Zhang X, Xiang Z, Zhang J. Combination Therapy With Various Combinations of Aliskiren, Valsartan, and Hydrochlorothiazide in Hypertensive Patients Not Adequately Responsive to Hydrochlorothiazide Alone. The Journal of Clinical Hypertension. 2009;11(6):324–32. [PubMed] [Google Scholar].